DiaGenic slashes payroll over Alzheimer's Dx study failure; India's local device startups have small-town edge;

@FierceMedDev: Sign up for our new publication, FierceDiagnostics, launching with its first weekly newsletter tomorrow. Sign up here | Follow @FierceMedDev

@DamianFierce: Covidien has opened the doors of a new $21M South Korean R&D shop. More | Follow @DamianFierce

@MarkHFierce: Edwards, fresh from a patent lawsuit victory, is heralding a German injunction on Medtronic CoreValve sales. Story | Follow @MarkHFierce

@MichaelGFierce: Ceptaris nets first-ever FDA approval for topical lymphoma chemo gel. More from FierceDrugDelivery | Follow @MichaelGFierce

> Norway's DiaGenic is slashing its payroll after one of its in-development Alzheimer's disease diagnostics failed to meet study goals. News (reg. req.)

> Siemens Healthcare's ($SI) plan for the future involves a deep dive into companion diagnostics, and Senior Vice President Trevor Hawkins sat down with News Medical to detail the German company's take on the growing market. Interview

> While multinational medical device companies have descended on India's largest cities, local startups still have a leg up in the nation's smaller towns, according to a report. More

> Magellan won U.S. approval for its lead poisoning diagnostic test. Story

> Abiomed ($ABMD) landed a major government contract with the U.S. Department of Veteran's Affairs to include its Impella heart pump on the VA Federal Supply Schedule. Story

> Cook Medical has secured expanded Medicare coverage for its Zilver PTX stent. News

> Miami's Sanomedics has nailed down a $5 million credit facility, money it will use to complete two acquisitions. Item

Biotech News

@FierceBiotech: Syndax snags $26.6M round for Phase III breast cancer study. More | Follow @FierceBiotech

@JohnCFierce: Patient advocacy or Amgen's blockbuster protection act? Biosimilars bills advance. Report | Follow @JohnCFierce

> Acura investors feel the pain as abuse-deterrence tech flops in PhII. More

> Tiny Catalyst soars after rare disease drug scores 'breakthrough' at FDA. News

Pharma News

@FiercePharma: Sudden CFO departure at Actelion, just as Swiss drug maker wraps up Ceptaris buyout. More | Follow @FiercePharma

@EricPFierce: Swiss CMO Siefried building a manufacturing plant in China. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: From FierceVaccines: Low vaccination rate at megachurch linked to measles outbreak. Story | Follow @CarlyHFierce

> China arrests British couple for trafficking in private information. News

> Bayer's Nexavar in FDA fast lane for thyroid cancer use. Report

> Akorn buys rival Hi-Tech for $640M. Article

> Lonza will cut 200 at Massachusetts plant by end of year. Story

Biotech Research News

@EmilyMFierce: Omega-3 alleviates ADHD symptoms in rats. More | Follow @EmilyMFierce

> High copper levels implicated in Alzheimer's disease. Story

> Single injection could provide new treatment for melanoma. Article

> New target to battle Parkinson's discovered. News

> Gene therapy in mice improves Rett syndrome. More

> Sodium 'switch' could provide target to treat brain disorders. Item

Pharma Manufacturing News

> Akorn buys Hi-Tech for $640M to tap manufacturing expertise. Report

> Amarin asks FDA to approve Novasep as Vascepa partner. Story

> Lonza starting job cuts at troubled U.S. biologics plant. Article

> Ontario helps Pillar5 expand plant. Item

> Another Fresenius plant in FDA crosshairs. More

Suggested Articles

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.